Research Studies & Clinical Trials

Overview/Purpose

This is an open-label, controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who are on antiretroviral therapy (ART)-mediated suppression. Participants will be randomly assigned to receive either letermovir once daily or no anti-CMV treatment, for 48 weeks.

Interested in Volunteering?

Do you want to participate in a study related to HIV & Aging? Explore a treatment that looks at whether an oral drug decreases inflammation.

Eligibility Criteria:

• Age 40 or older
• HIV with undetectable viral load on HIV treatment for at least 48 weeks
• Positive for CMV (the study will perform the test)



Principal Investigator:

Kara Chew, MD, MS



For more information, please contact the UCLA CARE Center:

[email protected]
310-843-2015


If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.

Additional Resources: